According to the statistics of the Oriental Wealth Network institutional survey, on November 16, a total of 43 companies were surveyed by institutions, and the industries intensively investigated by institutions mainly involved communications, electronics, medicine and other industries
.
Among them, in the pharmaceutical industry, a total of 5 companies have been concerned by institutions, namely Jiudian Pharmaceutical, Wohua Pharmaceutical, Saito Biotechnology, Yingke Medical, and Shuyu Civilian
.
43 companies were investigated by institutions, and pharmaceutical and other industries were favored (Image source: Pharmaceutical Network)
Among them, Jiudian Pharmaceutical received 9 institutions on November 16, including 2 asset management companies, 2 fund management companies, 1 securities company, etc
.
In the research activities, the company's product procurement, business development, future sales strategy, follow-up R&D layout and other aspects have attracted much attention
from institutions.
Anti-inflammatory and analgesic product Loxoprofen sodium gel patch is the company's leading product, with strong growth momentum, and the sales revenue in the first three quarters was 895 million yuan, exceeding the whole year of last year, a year-on-year increase of 51.
54%.
Jiudian Pharmaceutical said that the company has laid out a number of anti-inflammatory and analgesic products
in the field of topical transdermal drug delivery.
Loxoprofen sodium gel patch has been mainly sold in the hospital market, and this year began to expand OTC channels, this year's goal is to cover the top 100 chain pharmacies and some regional chain leading pharmacies
.
In general, the company's R&D layout will form a good product echelon in the future, and strive to build a "Jiuyue" paste brand and enhance brand value
.
At present, the company is vigorously developing transdermal drug delivery preparations, including gel patches, topical drug patches, systemic drug delivery patches, gels and creams, etc.
, there are more than 15 varieties under research, the proportion of generic drugs and improved new drugs is close, the indications are mainly analgesia and geriatric diseases, and the company also has innovative drug projects under development
.
In addition, the company also actively develops APIs and excipients related to topical preparations to solve the neck problem
of key excipients of topical preparations.
In addition to Jiudian Pharmaceutical, the number of civilian reception institutions of Wohua Pharmaceutical, Saito Biotechnology, Yingke Medical and Shuyu is all 1, and the subdivisions of these companies involve traditional Chinese medicine, APIs, medical devices, pharmaceutical business, etc
.
Most of the issues that institutions are concerned about are based on the industry environment in which the company
operates.
For example, at the collective reception day of investors, in response to the impact of rising prices of Chinese medicinal materials and energy on the company's profits, the company said that in recent years, the prices of Chinese medicinal materials and energy have continued to rise, and they have fluctuated greatly
.
So far, the company's main raw medicinal materials have a large inventory, which has smoothed the trend
of rising prices to a certain extent.
In the future, if the price of raw medicinal materials continues to rise, it will greatly affect the company's product costs
.
The company's employees overcome difficulties and avoid peaks and valleys through flexible production organization, and minimize the adverse impact
of rising energy prices.
In addition, regarding the impact of the recommended downward revision of the hypertension diagnostic criteria on the company's performance, the company replied that "the reduction of the hypertension diagnostic criteria is expected to have a benign impact on the sales of Wohua Heart Cresol tablets, but the extent of the impact is not yet certain
.
" ”
Saito Biotech's plan in 2023 has attracted the attention of investors, the company said that in 2023, it will develop in several dimensions such as "continue to implement the industrial upgrading strategy and improve the management level", "implement comprehensive budget management, continue to reduce costs and increase efficiency", "ensure the steady landing of veterinary drugs and high-end respiratory APIs", and further increase investment in high-end intermediates business with high gross profit and high added value, and strive to reach a new level
in this field.
In the field of respiratory high-end characteristic APIs and veterinary APIs, we have achieved predetermined production and sales, and the declaration of scheduled new products is carried out
on schedule.
In the field of preparations, Lisapharma makes use of the existing product reserve advantages and R&D advantages of finished preparations, realizes the resource sharing of pharmaceutical R&D platforms at home and abroad, accelerates the domestic registration of overseas drugs, and strives to expand the domestic sales
of finished preparations.
In response to the question of whether there is a plan to expand production capacity in the future, Yingke Medical said that the disposable glove industry is currently in a cyclical adjustment stage, and the industry is generally facing a certain bottleneck, in the current industry situation, the company will remain cautious, adjust marketing strategies, capacity construction progress or plans in time according to market changes, and go all out to spend this challenging industry reshuffle period
.
The company remains optimistic about the future global glove market demand, and will continue to strive to cultivate the global market, enhance brand influence, give full play to the company's existing advantages in production, capital, sales channels and other aspects, and strive to occupy more market share
.
Shuyu civilians said for this year's expansion layout inside and outside the province, the company adheres to the "chain operation, scale development" business ideas, adopts the strategy of deeply cultivating the provincial market, steadily expanding the market outside the province, taking the Shandong market as the core, facing the regional expansion of the country, continuing to consolidate the network layout and brand advantages of the advantageous market, the company adheres to the self-operated store business model, deeply develops and consolidates the existing market, continuously expands the regional market share, and at the same time through a combination of new openings, mergers and acquisitions, franchises and cooperation.
Quickly expand into blank markets
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
